

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07D 239/48, 239/46, A61K 31/506, A61P 25/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 00/59893</b> (43) International Publication Date: <b>12 October 2000 (12.10.00)</b>						
(21) International Application Number: <b>PCT/US00/09004</b> (22) International Filing Date: <b>5 April 2000 (05.04.00)</b> (30) Priority Data: <table><tr><td><b>60/127,923</b></td><td><b>6 April 1999 (06.04.99)</b></td><td><b>US</b></td></tr><tr><td><b>60/128,842</b></td><td><b>12 April 1999 (12.04.99)</b></td><td><b>US</b></td></tr></table> (71) Applicant (for all designated States except US): <b>KRENITSKY PHARMACEUTICALS INC. [US/US]; Four University Place, 4611 University Drive, Durham, NC 27707 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>KELLEY, James, L. [US/US]; 10928 Raven Rock Drive, Raleigh, NC 27614 (US). KRENITSKY, Thomas, A. [US/US]; 106 Laurel Hill Road, Chapel Hill, NC 27514 (US). BEAUCHAMP, Lilia, M. [US/US]; 3003 Wycliff Road, Raleigh, NC 27607 (US).</b> (74) Agents: <b>HUMPHREY, Christopher, M. et al.; Alston &amp; Bird LLP, P.O. Drawer 34009, Charlotte, NC 28234-4009 (US).</b>		<b>60/127,923</b>	<b>6 April 1999 (06.04.99)</b>	<b>US</b>	<b>60/128,842</b>	<b>12 April 1999 (12.04.99)</b>	<b>US</b>	(81) Designated States: <b>AE, AG, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), DM, DZ, EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>60/127,923</b>	<b>6 April 1999 (06.04.99)</b>	<b>US</b>							
<b>60/128,842</b>	<b>12 April 1999 (12.04.99)</b>	<b>US</b>							
(54) Title: <b>NEUROTROPHIC THIO SUBSTITUTED PYRIMIDINES</b>									
(57) Abstract <p>The present invention relates to a series of substituted thiopyrimidines, to pharmaceutical compositions which contain them, to methods for their preparation and to their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral systems.</p>									

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## NEUROTROPHIC THIO SUBSTITUTED PYRIMIDINES

## BACKGROUND OF THE INVENTION

- The present invention relates to novel derivatives of a series of substituted pyrimidines, to pharmaceutical compositions which contain them, to methods for their preparation and to their use in therapy, particularly in the treatment of neurodegenerative or other neurological disorders of the central and peripheral systems including nerve injuries.
- 5 Dementing disorders such as age-related cognitive disorders, e.g., senility or Alzheimer's disease are medical conditions for which there are currently only limited therapies. Although studies suggest that multiple neurotransmitter systems are involved in senile dementia, a loss of cholinergic neurons and a severe depletion of choline acetyltransferase
- 15 appear to show the earliest and strongest correlations with functional cognitive impairment [see P.T. Francis et al., *Neurochemical Studies of Early-onset Alzheimer's Disease*. *N. Engl. J. Med.*, 313, 7 (1985); R.T. Bartus et al., *The Cholinergic Hypothesis: A Historical Overview, Current Perspective, and Future Directions*. *Ann. N. Y. Acad. Sci.*, 444, 332 (1985);
- 20 F. Hefti and L.S. Schneider, *Nerve Growth Factor and Alzheimer's Disease*, *Clin. Neuropharmacol.*, 14, S62 (1991)]. Several groups have attempted to stimulate cholinergic activity by blocking the breakdown of acetylcholine with acetylcholine esterase inhibitors or by introducing muscarinic or nicotinic agonists [see R.T. Bartus et al., *The Cholinergic Hypothesis of*
- 25 *Geriatric Memory Dysfunction*. *Science*, 217, 408 (1982); J. Varghese et al., Chapter 21. *Alzheimer's Disease: Current Therapeutic Approaches*. *Annu. Rep. Med. Chem.*, 28, 197 (1993)]. The approved drugs Cognex and Aricept are acetylcholine esterase inhibitors.
- 30 Nerve growth factor (NGF) is the best characterized neurotrophic factor that is capable of inducing cell differentiation of neural cells and promoting neurite sprouting. The neurotrophic protein NGF primarily affects

cholinergic neurons in the central nervous system and may be necessary for their survival [see F. Hefti and P.A. Lapchak, Pharmacology of Nerve Growth Factor in the Brain. Adv. Pharmacol., 24, 239 (1993)]. NGF is not systemically bioavailable, but if it is injected or infused directly into brain, it prevents neuronal cell loss and restores cognitive function in aged or lesioned rats or monkeys [see W. Fischer et al., NGF Improves Spatial Memory in Aged Rodents as a Function of Age. J. Neurosci., 11, 1889 (1991)]. NGF effects ultimately result in the stimulation of choline acetyltransferase, the enzyme for biosynthesis of acetylcholine and the promotion of neurite growth. Consequently, small molecules that produce neurotrophic or "nerve growth factor-like" (NGF-like) properties in mammalian cell cultures have potential for use in the treatment of dementing disorders such as age-related senility or Alzheimer's disease and other neurodegenerative conditions such as peripheral neuropathies, Parkinson's, stroke damage, transient ischemic attacks, trauma-head injuries or other nerve injuries.

There are several reports of small molecules that exhibit various aspects of NGF-like activity. Isaxonine [2-(isopropylamino)pyrimidine] was developed as a neurotrophic pharmaceutical but the clinical application was withdrawn, possibly due to toxicological effects [see S. Lehmann et al., Neurite Outgrowth of Neurons of Rat Dorsal Root Ganglia Induced by New Neurotrophic Substances with Guanidine Group. Neurosci. Lett., 152, 57 (1993)]. Several 2-(piperazino)pyrimidine derivatives were reported to possess NGF-like activity and are being studied further for use in treating CNS degenerative diseases [see A. Awaya et al., Neurotrophic Pyrimidine Heterocyclic Compounds. Biol. Pharm. Bull., 16, 248 (1993)]. AIT-082 (4[[3-(1,6-dihydro-6-oxo-9-purin-9-yl)-1-oxopropyl]amino]benzoic acid) is reported to enhance NGF action in cultured PC-12 cells and to restore age-induced working memory deficits in mice [see P.J. Middlemiss et al., AIT-082, A Unique Purine Derivative, Enhances Nerve Growth Factor Mediated Neurite Outgrowth from PC-12 cells. Neuroscience Lett., 199, 131 (1995)].

The compound SR57746A is reported to have nerve growth factor potentiating activity and is in clinical trials [see Fournier J, et al. Protective Effects of SR57746A in Central and Peripheral Models of Neurodegenerative Disorders in Rodents and Primates. Neuroscience, 5 55(3), 629-41, Aug 1993; US Patents 5,270,320 and 5,462,945]. In addition, EP0372934, EP0459819 and U.S. Patent 5,075,305 disclose substituted pyrimidines having NGF-like properties and its possible use in treating CNS degenerative diseases like Alzheimer's disease as well as peripheral neuropathies and other peripheral nervous system disorders.


10

#### SUMMARY OF THE INVENTION

We have now discovered a series of substituted pyrimidines that demonstrate NGF-like activity and/or enhancement of NGF activity in PC12 cells. The compounds stimulated both neurite outgrowth and choline  
15 acetyltransferase activity in *in vitro* experiments. Such activities are predictive for causing increased choline acetyltransferase activity in rat striatum and improving cognitive performance in animal models of age-induced working memory deficits by potentiating the activity of endogenous NGF in the brain. [see P.J.. Middlemiss et al., AIT-082, A Unique Purine  
20 Derivative, Enhances Nerve Growth Factor Mediated Neurite Outgrowth from PC-12 cells. Neuroscience Let., 199, 131 (1995); A.J. Glasky et al., Effect of AIT-082, a Purine Analog, on Working Memory in Normal and Aged Mice. Pharmacol. Biochem. Behav., 47, 325 (1994); R. Morris, Developments of a Water-maze Procedure for Studying Spatial Learning in  
25 the Rat. J. Neurosci. Methods, 11, 47 (1984)].

## DETAILED DESCRIPTION OF THE INVENTION

According to the present invention, there are provided novel compounds of Formula I:



Formula I

wherein

R<sub>1</sub> is NHR<sub>4</sub>, wherein R<sub>4</sub> is C6-10 aryl, C2-10alkyl, (C1-6alkyl)((C3-9cycloalkyl)(CH<sub>2</sub>)<sub>q</sub> or (C1-6alkyl)((C6-10aryl)(CH<sub>2</sub>)<sub>q</sub>, wherein j is 0-2 and q is 0-6, or (C1-6alkyl)((C4-9heterocycloalkyl)(CH<sub>2</sub>)<sub>q</sub> wherein j is 0-2, q is 0-6 and the heterocyclic ring contains one or more heteroatoms which may be the same or different and are O, S, N or NR' (wherein R' is hydrogen, C1-6 alkyl, hydroxyC2-6 alkyl, mercaptoC2-6alkyl, C1-6alkyloxyC2-6alkyl, C1-6alkylthioC2-6alkyl, C6-10arylcarbonyl, C1-7alkylcarbonyl, C1-7alkylsulfonyl or C6-10arylsulfonyl); or

R<sub>1</sub> is piperazino or homopiperazino wherein the 4-N is substituted with a carbonylR<sub>5</sub> or sulfonylR<sub>5</sub>, wherein R<sub>5</sub> is

H (excluding sulfonyl),  
 C1-10alkyl,  
 C3-10alkenyl,  
 C3-10alkynyl,  
 C1-6alkyloxy,  
 C1-6alkyloxyC1-6alkyl,  
 C1-6alkylthioC1-6alkyl,  
 C1-6alkylamino,

C6-10aryl(CH<sub>2</sub>)<sub>q</sub> wherein q is 0-6,  
C6-10aryloxy(CH<sub>2</sub>)<sub>q</sub> wherein q is 0-6,  
C6-10arylamino(CH<sub>2</sub>)<sub>q</sub> wherein q is 0-6,  
(C1-6alkyl)<sub>j</sub>(C3-9cycloalkyl)(CH<sub>2</sub>)<sub>q</sub> wherein j is 0-2 and q is 0-  
5 6, or (C1-6alkyl)<sub>j</sub>(C4-9heterocycloalkyl)(CH<sub>2</sub>)<sub>q</sub> wherein j is 0-  
2, q is 0-6 and the heterocyclic ring contains one or more  
heteroatoms which may be the same or different and are O,  
S, N or NR', wherein R' is hydrogen, C1-6alkyl, hydroxyC2-  
6alkyl, mercaptoC2-6alkyl, C1-6alkyloxyC2-6alkyl, C1-  
10 6alkylthioC2-6alkyl, C6-10arylcarbonyl, C1-7alkylcarbonyl,  
C1-7alkylsulfonyl or C6-10arylsulfonyl,  
and wherein C atoms of R<sub>4</sub> and R<sub>5</sub> may optionally be substituted with one  
or more substituents selected from the group consisting of  
hydroxyl,  
15 halogen,  
thiol,  
oxo,  
thioxo,  
carboxy,  
20 carboxamide,  
C1-7alkyl carbonyl,  
C1-7alkyl thiocarbonyl,  
C1-8alkyloxy,  
C1-8alkylthio,  
25 C1-8alkylsulfinyl,  
C1-8alkylsulfonyl,  
C1-5alkyloxyC1-5alkyl,  
C1-5alkylthioC1-5alkyl,  
C1-5alkylsulfinylC1-5alkyl, and  
30 C1-5alkylsulfonylC1-5alkyl;

R<sub>2</sub> is H or NH<sub>2</sub>;

R<sub>3</sub> is H;

X is a C6-10 aryl ring optionally substituted with one or more substituents

5 selected from the group consisting of

halogen,

hydroxyl,

C1-6alkyl,

hydroxyC1-6alkyl,

10 oxoC2-7alkyl,

C2-7alkenyl,

C2-7alkynyl,

C1-6alkoxy,

CF<sub>3</sub>,

15 CF<sub>3</sub>C1-6alkyl,

OCF<sub>3</sub>, and

CF<sub>3</sub>C1-6alkoxy;

or pharmaceutically acceptable esters, amides, esters, amides, salts or  
20 solvates thereof.

The present invention includes all enantiomeric and diastereomeric forms  
of the compounds of Formula I either individually or admixed in any  
proportion.

25

The present invention further includes prodrugs and active metabolites of  
the compounds of Formula I. A prodrug includes any compound which,  
when administered to a mammal, is converted in whole or in part to a  
compound of Formula I. An active metabolite is a physiologically active  
30 compound which results from the metabolism of a compound of Formula I,  
or a prodrug thereof, when such compound or prodrug is administered to a  
mammal.

The compounds of Formula I above and their pharmaceutically acceptable esters, amides, salts or solvates are sometimes hereinafter referred to as "the compounds according to the invention".

5

By "alkyl" is meant straight or branched chain alkyl. The alkyl groups may be optionally substituted with hydroxy, amino or halogen.

By "aryl" is meant an aromatic ring such as phenyl or naphthyl. The aryl groups may be optionally substituted with hydroxy, amino or halogen.

10

By "heteroaryl" is meant a ring containing 1 to 4 heteroatoms selected from the group consisting of N, O and S.

By "halogen" is meant F, Cl, Br or I.

15

Preferred compounds of Formula I are those wherein X is substituted phenyl; and pharmaceutically acceptable esters, amides, salts or solvates thereof.

20

Further preferred compounds of Formula I are those wherein R<sub>1</sub> is C1-10alkylcarbonylpiperizino, hydroxyC3-9cycloalkylamino, or hydroxyC6-10arylamino, and X is substituted phenyl, and pharmaceutically acceptable esters, amides, salts or solvates thereof.

25

Most preferred compounds of Formula I are those wherein R<sub>1</sub> is 4-acetylpiperazino, 4-oxocyclohexylamino, trans-4-hydroxycyclohexylamino, 4-hydroxyanilino, or 4-(2-hydroxyethylamino); X is phenyl optionally substituted with 4-chloro, 2,4 dichloro, 4-bromo, 2-fluoro-4-chloro, 2-chloro-4-fluoro, 2-methyl-4-chloro, 4-methyl, or 4-ethyl; and R<sub>2</sub> is NH<sub>2</sub>; and pharmaceutically acceptable esters, amides, salts or solvates thereof.

30

Specifically preferred compounds of Formula I are:

- 4-acetylpiperazino-2-amino-5-(4-chlorophenylthio)pyrimidine
- 5 4-acetylpiperazino-2-amino-5-(2,4-dichlorophenylthio)pyrimidine
- 4-acetylpiperazino-2-amino-5-(4-bromophenylthio)pyrimidine
- 4-acetylpiperazino-2-amino-5-(2-fluoro-4-chlorophenylthio)pyrimidine
- 4-acetylpiperazino-2-amino-5-(2-chloro-4-fluorophenylthio)pyrimidine
- 4-acetylpiperazino-2-amino-5-(2-methyl-4-chlorophenylthio)pyrimidine
- 10 4-acetylpiperazino-2-amino-5-(4-methylphenylthio)pyrimidine
- 4-acetylpiperazino-2-amino-5-(4-ethylphenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(4-chlorophenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(2,4-dichlorophenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(4-bromophenylthio)pyrimidine
- 15 2-amino-4-oxocyclohexylamino-5-(2-fluoro-4-chlorophenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(2-chloro-4-fluorophenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(2-methyl-4-chlorophenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(4-methylphenylthio)pyrimidine
- 2-amino-4-oxocyclohexylamino-5-(4-ethylphenylthio)pyrimidine
- 20 2-amino-4- hydroxycyclohexylamino-5-(4-chlorophenylthio)pyrimidine
- 2-amino-4- hydroxycyclohexylamino-5-(2,4-dichlorophenylthio)pyrimidine
- 2-amino-4- hydroxycyclohexylamino-5-(4-bromophenylthio)pyrimidine
- 2-amino-4- hydroxycyclohexylamino-5-(2-fluoro-4-chlorophenylthio)  
pyrimidine
- 25 2-amino-4- hydroxycyclohexylamino-5-(2-chloro-4-fluorophenylthio)  
pyrimidine
- 2-amino-4- hydroxycyclohexylamino-5-(2-methyl-4-chlorophenylthio)  
pyrimidine
- 2-amino-4- hydroxycyclohexylamino-5-(4-methylphenylthio)pyrimidine
- 30 2-amino-4- hydroxycyclohexylamino-5-(4-ethylphenylthio)pyrimidine
- 2-amino-4- hydroxyanilino-5-(4-chlorophenylthio)pyrimidine
- 2-amino-4- hydroxyanilino-5-(2,4-dichlorophenylthio)pyrimidine

- 2-amino-4- hydroxyanilino-5-(4-bromophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(2-fluoro-4-chlorophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(2-chloro-4-fluorophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(2-methyl-4-chlorophenylthio)pyrimidine  
5 2-amino-4- hydroxyanilino-5-(4-methylphenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(4-ethylphenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-chlorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(2,4-dichlorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-bromophenylthio)pyrimidine  
10 2-amino-4-(2-hydroxyethylamino)-5-(2-fluoro-4-chlorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(2-chloro-4-fluorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(2-methyl-4-chlorophenylthio)  
pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-methylphenylthio)pyrimidine  
15 2-amino-4-(2-hydroxyethylamino)-5-(4-ethylphenylthio)pyrimidine  
2-Amino-5-(2-chloro-4-ethylphenylthio)-4-(trans-4-hydroxycyclohexylamino)  
pyrimidine  
2-Amino-5-(2,6-dichlorophenylthio)-4-(trans-4-hydroxycyclohexylamino)  
pyrimidine  
20 2-Amino-5-(4-chloro-2-methylphenylthio)-4-  
(trans-4-hydroxycyclohexylamino)pyrimidine  
2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-  
(4-trifluoromethylphenylthio)pyrimidine  
2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(4-methylphenylthio)  
25 pyrimidine  
2-Amino-5-(4-chloro-2-fluorophenylthio)-4-  
(trans-4-hydroxycyclohexylamino)pyrimidine  
2-Amino-5-(4-chloro-2-methylphenylthio)-4-  
(trans-4-hydroxycyclohexylamino)pyrimidine  
30 2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(4-methylphenylthio)  
pyrimidine  
2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(phenylthio)pyrimidine

- 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-2-hydroxycyclohexylamino)  
pyrimidine
- 5 2-Amino-5-(4-chlorophenylthio)-4-(cis-4-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(cis-3-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(cis-2-hydroxycyclohexylamino)  
10 pyrimidine
- 2-Amino-5-(2,4-dichlorophenylthio)-4-(4-oxocyclohexylamino)pyrimidine
- 2-Amino-5-(2,4,6-trichlorophenylthio)-4-(4-oxocyclohexylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-  
(trans-4-(hydroxymethyl)cyclohexylamino)pyrimidine
- 15 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-  
(hydroxymethyl)cyclohexylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-  
(cis-4-(hydroxymethyl)cyclohexylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-4-hydroxycyclohexylmethylamino)  
20 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-hydroxycyclopentylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-2-hydroxycyclopentylamino)  
pyrimidine
- 25 2-Amino-5-(4-chlorophenylthio)-4-(cis-3-hydroxycyclopentylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(cis-2-hydroxycyclopentylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-  
30 (trans-3-(hydroxymethyl)cyclopentylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-2-(hydroxymethyl)  
cyclopropylmethylamino)pyrimidine

- 2-Amino-5-(4-chlorophenylthio)-4-(cis-2-(hydroxymethyl)  
cyclopropylmethylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-  
(1-hydroxycyclopropylmethylamino)pyrimidine  
5 2-Amino-5-(4-chlorophenylthio)-4-  
(1-hydroxycyclopentylmethylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxy-1-methyl(ethylamino))  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(1-hydroxymethyl-ethylamino)pyrimidine  
10 2-Amino-5-(4-chlorophenylthio)-4-(1,1-dimethyl-2-hydroxy(ethylamino))  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(1-hydroxymethyl-2-hydroxy(ethylamino))  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxy-1-hydroxymethyl-1-methyl  
15 (ethylamino))pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(tris(hydroxymethyl)methylamino)  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(2,3-dihydroxypropylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(3,4-dihydroxybutylamino)pyrimidine  
20 2-Amino-5-(4-chlorophenylthio)-4-(2-methoxyethylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(2-(2-hydroxyethylamino)ethylamino)  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-((2-aminoethyl)(2-hydroxyethyl)amino)  
pyrimidine  
25 2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxyethylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(4-(2-hydroxyethyl)piperazinoamino)  
pyrimidine  
2-Amino-5-(2,4-dichlorophenylthio)-4-(4-(2-hydroxyethyl)piperazinoamino)  
pyrimidine  
30 2-Amino-5-(2-chloro-4-ethylphenylthio)-4-(4-acetylpiperazino)pyrimidine  
2-Amino-5-(2,4-dichlorophenylthio)-4-(4-acetylpiperazino)pyrimidine  
2-Amino-5-(2,6-dichlorophenylthio)-4-(4-acetylpiperazino)pyrimidine

- 2-Amino-5-(4-chloro-2-methylphenylthio)-4-(4-acetylpiperazino)pyrimidine  
2-Amino-4-(4-acetylpiperazino)-5-(4-trifluoromethylphenylthio)pyrimidine  
2-Amino-5-(2-chloro-4-fluorophenylthio)-4-(4-acetylpiperazino)pyrimidine  
2-Amino-5-(4-chloro-2-methylphenylthio)-4-(4-acetylpiperazino)pyrimidine  
5 2-Amino-4-(4-acetylpiperazino)-5-(4-methylphenylthio)pyrimidine  
2-Amino-4-(4-acetylpiperazino)-5-(phenylthio)pyrimidine  
5-(4-Chlorophenylthio)-4-(4-acetylpiperazino)pyrimidine;  
5-(2,4-Dichlorophenylthio)-4-(4-acetylpiperazino)pyrimidine;  
4-(4-Acetoxyanilino)-2-amino-5-(4-chlorophenylthio)pyrimidine  
10 4-(4-Acetylhomopiperazino)-2-amino-5-(4-chlorophenylthio)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-[2-hydroxy-1-(R-ethyl)-ethylamino]  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-[[2-(morpholino)ethylamino]pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(1-morpholinoamino)pyrimidine  
15 2-Amino-5-(4-chlorophenylthio)-4-(4-hydroxyphenethylamino)pyrimidine  
2-Amino-4-(trans-2-hydroxycyclohexylaminomethyl)-5-(4-chlorophenylthio)  
pyrimidine  
2-Amino-4-(4-aminomethyl-N-acetylpiperidiny)-5-(4-chlorophenylthio)  
pyrimidine  
20 2-Amino-4-(1-hydroxy-1-aminomethylcyclohexyl)-5-(4-chlorophenylthio)  
pyrimidine  
4-(4-trans-Acetoxycyclohexylamino)-2-amino-5-(4-chlorophenylthio)  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(4-trans-isobutyloxy-cyclohexylamino)  
25 pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(4-trans-trimethylacetoxycyclohexylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(4-trans-propionyloxy-cyclohexylamino)  
pyrimidine  
30 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-benzoyloxy-cyclohexylamino)  
pyrimidine

- 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-(4-chlorobenzoyloxy)-  
cyclohexylamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(4-trans-L-valyloxycyclohexylamino)  
pyrimidine  
5 4-(4-Acetoxypheylamino)-2-amino-5-(4-chlorophenylthio)pyrimidine  
2-Amino-4-phenylamino-5-(4-chlorophenylthio)pyrimidine  
2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-hydroxyphenylthio)  
pyrimidine  
2-Amino-4-(acetamidophenylamino)-5-(4-chlorophenylthio)pyrimidine  
10 2-Amino-5-(4-chlorophenylthio)-4-(bis-hydroxymethylmethylamino)  
pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(4-hydroxy-3-nitro-anilino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(hydroxyamino)pyrimidine  
2-Amino-5-(4-chlorophenylthio)-4-(methoxyamino)pyrimidine  
15 2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxyethoxyamino)pyrimidine

or pharmaceutically acceptable esters, amides, salts or solvates thereof.

In one aspect of the invention there is provided the compounds according  
20 to the invention for use in medical therapy, particularly for the treatment of  
neurodegenerative or neurological disorders of the central or peripheral  
nervous systems.

Examples of nervous system disorders which may be treated in  
25 accordance with the invention include dementing disorders such as age-  
related senility, senile dementia or Age Related Mental Impairment (ARMI),  
cerebral ataxia, Parkinson's disease, Alzheimer's disease, peripheral  
neuropathy, cognitive disorders secondary to stroke or trauma and  
attention-deficit hyperactivity disorder. In addition, nerve injuries, for  
30 example, spinal cord injuries, that require neuroregeneration may also be  
treated in accordance with the invention.

In a further aspect of the present invention there is included:

a) A method for the treatment of neurodegenerative or neurological disorders of the central or peripheral nervous systems which comprises  
5 treating the subject e.g., a mammal, such as a human, with a therapeutically effective amount of a compound according to the invention.

b) Use of a compound according to the invention in the manufacture of a medicament for the treatment of any of the above-mentioned disorders:

10

Examples of pharmaceutically acceptable salts of the compounds according to the invention include acid addition salts. However, salts of non-pharmaceutically acceptable acids may be of utility in the preparation and purification of the compounds of the invention.

15

Preferred salts include those formed from hydrochloric, hydrobromic, sulfuric, phosphoric, citric, tartaric, lactic, pyruvic, acetic, succinic, fumaric, maleic, oxaloacetic, methanesulfonic, ethansulfonic, p-toluenesulfonic, benzenesulfonic and isethionic acids.

20

The compounds according to the invention and pharmaceutically acceptable esters, amides, salts or solvates thereof may be employed in combination with other therapeutic agents for the treatment of the above disorders. Examples of such further therapeutic agents include Cognex,  
25 Aricept and other agents (e.g., acetylcholine esterase inhibitors, muscarinic or nicotinic receptor agonists, MAO inhibitors) that are effective for the treatment of neurodegenerative or neurological disorders of the central or peripheral nervous systems. The component compounds of such combination therapy may be administered simultaneously in either  
30 separate or combined formulations, or at different times, e.g., sequentially such that a combined effect is achieved.

While it is possible for compounds according to the invention to be administered as the raw chemical, it is preferable to present them as a pharmaceutical formulation. The formulations of the present invention comprise a compound of Formula I, as above defined, or a

5 pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers therefor and optionally other therapeutic ingredients. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

10 The formulations include those suitable for oral, parenteral (including subcutaneous, transdermal, intradermal, intramuscular and intravenous), rectal and topical (including dermal, buccal and sublingual) administration although the most suitable route may depend upon, for example, the

15 condition and disorder of the recipient. The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association a compound of Formula I or a pharmaceutically acceptable salt thereof (active ingredient) with the carrier which constitutes

20 one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.

25 Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion, or a water-in-oil liquid

30 emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, lubricating, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.

Formulations for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example, water-for-injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

Formulations suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Such patches suitably contain the active compound 1) in an optionally buffered, aqueous solution or 2) dissolved and/or dispersed in an adhesive or 3) dispersed in a polymer. A suitable concentration of the active compound is about 1% to 35%, preferably about 3% to 15%. As one particular possibility, the active compound may be delivered from the patch by electrotransport or iontophoresis, as generally described in Pharmaceutical. Res., 3(6), 318 (1986).

Formulations for rectal administration may be presented as suppository with the usual carriers such as cocoa butter or polyethylene glycol.

5 Formulations for topical administration in the mouth, for example, buccally or sublingually, include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.

10

Preferred unit dosage formulations are those containing an effective dose, as hereinbelow recited, or an appropriate fraction thereof, of the active ingredient.

15 It should be understood that in addition to the ingredients particularly mentioned above, the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.

20

Tablets or other forms of presentation in discrete units may conveniently contain an amount of compound of the Formula I which is effective for each of the above-mentioned indications at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually between 10

25

mg to 250 mg.

For the above-mentioned conditions and disorders, the compounds of the Formula I are preferably administered orally or by injection (intraparenteral or subcutaneous). The precise amount of compound administered to a  
30 patient will be the responsibility of the attendant physician. However, the dose employed will depend on a number of factors, including the age and sex of the patient, the precise disorder being treated, and its severity. Also

the route of administration is likely to vary depending on the condition and its severity.

For each of the above-mentioned indications the compounds of the  
5 Formula I may be administered orally. The dose range for adult humans is generally from about 10 to 4000 mg/day and preferably from about 100 to 1000 mg/day. It may be advantageous to administer an initial dose of 200 to 2000 mg the first day then a lower dose of 100 to 1000 mg on subsequent days.

10

For each of the above-mentioned indications, the compounds according to the invention may be administered by injection at a dose of from about 1 to 2000 mg/day, and preferably from about 5 to 1000 mg/day.


15 The present invention further includes processes for the preparation of compounds of Formula I and esters, amides, salts or solvates thereof.

The compounds of Formula (I) and their esters, amides, salts and solvates may be prepared in accordance with the present invention by those  
20 methods hereinafter described, or in any manner known in the art for the preparation of compounds of analogous structure.

By way of illustration which does not limit the present invention, the compounds, esters, amides, salts and solvates of Formula (I) may be  
25 prepared by a process which comprises:

30

reacting a compound of Formula (II)




5

### Formula II

wherein  $R_2$ ,  $R_3$  and  $X$  are as hereinbefore defined and  $U$  is a leaving group, with an amine  $NH_2R_4$  wherein  $R_4$  is as hereinbefore defined, or with a monosubstituted piperazine. Suitable leaving groups include halogens such as chloride. The reaction is carried out in an organic solvent (e.g., ethanol, propanol) at a temperature of approximately  $20^\circ C$  to approximately  $120^\circ C$ . The compound of Formula (II) may be isolated and purified prior to reaction with the amine or may be used *in situ*.

Compounds of Formula (II) wherein  $U$  is a halogen atom can be prepared from compounds of Formula (III)

15




### Formula III

wherein  $R_2$ ,  $R_3$  and  $X$  are as hereinbefore defined, by reaction with a halogenating agent (e.g., phosphorous oxychloride, phosphorous pentachloride, or a Vilsmeier reagent created using oxalyl chloride and  $N,N$ -diisopropylformamide) in a suitable organic solvent (e.g., dichloromethane, 1,2-dichloroethane, toluene,  $N,N$ -dimethylformamide) at a

temperature of approximately 40°C to approximately 100°C.

Compounds of Formula (III) can be prepared from compounds of Formula (IV)

5




Formula IV

wherein R<sub>2</sub> and R<sub>3</sub> are as hereinbefore defined and W is a halogen atom  
10 such as bromo or chloro, by reaction with a suitable benzenethiol (e.g., 4-chlorobenzenethiol, 4-ethylbenzenethiol, 2,4-dichlorobenzenethiol) and a suitable base (e.g., potassium carbonate) in a suitable organic solvent (e.g., N,N-dimethylformamide, ethylene glycol, dimethylsulfoxide) at a temperature of 80°C to 140 °C.

15

Compounds of Formula (IV) can be prepared by various methods known in the art or are available from commercial sources.

Alternatively, compounds of Formula (III) can be prepared from compounds of Formula (V)




5

#### Formula V

wherein  $R_3$  and X are as hereinbefore defined, by reaction of an alkaline earth salt of Formula (V) with formamidine or guanidine in a suitable organic solvent (e.g., ethanol, methanol, 2-propanol, tert-butanol, tetrahydrofuran) at a temperature of approximately 60°C to the reflux

10 temperature.

Compounds of Formula (V) can be prepared from compounds of Formula (VI)



15


#### Formula VI

wherein X is as hereinbefore defined by reaction with an ester (e.g., ethyl formate) and a strong base (e.g., sodium hydride, potassium hydride, potassium tert-butoxide, sodium metal, lithium diisopropylamide) in a suitable organic solvent (e.g., tetrahydrofuran, ether, toluene) at a temperature of approximately 0°C to approximately 40°C.

Compounds of Formula (VI) can be prepared by various methods known in the art or are available from commercial sources.

25

Novel intermediates for the synthesis of compounds of Formula I are shown in Formula A:



5

Formula A

wherein X is as hereinbefore defined.

Specifically preferred intermediate compounds for synthesis of the above-  
10 listed specifically preferred compounds of Formula I are:

- 5-(phenylthio)isocytosine
- 5-(4-Methylphenylthio)isocytosine
- 5-(4-Chlorophenylthio)isocytosine
- 15 5-(4-Chloro-2-methylphenylthio)isocytosine
- 5-(4-Ethylphenylthio)isocytosine
- 5-(2-Chloro-4-fluorophenylthio)isocytosine
- 5-(2,4-Dichlorophenylthio)isocytosine
- 5-(4-Bromophenylthio)isocytosine
- 20 5-(2,4,6-trichlorophenylthio)isocytosine
- 5-(4-Trifluoromethylphenylthio)isocytosine
- 5-(4-Chlorophenylthio)-2-(diisopropylaminomethyleneamino)-4-chloropyrimidine
- 5-(2,4-Dichlorophenylthio)-2-(diisopropylaminomethyleneamino)-4-  
25 chloropyrimidine
- 5-(4-Chloro-2-fluorophenylthio)isocytosine, and
- 5-(2,6-Dichlorophenylthio)isocytosine.

- Esters and amides of compounds of Formula I can be made by reaction with a carbonylating agent (e.g., ethyl formate, acetic anhydride, methoxyacetyl chloride, benzoyl chloride, methyl isocyanate, ethyl chloroformate, methanesulfonyl chloride) and a suitable base (e.g., 4-dimethylaminopyridine, pyridine, triethylamine, potassium carbonate) in a suitable organic solvent (e.g., tetrahydrofuran, acetone, methanol, pyridine, N,N-dimethylformamide) at a temperature of 0°C to 60°C.
- Salts of the compounds of Formula I can be made from the free base form by reaction with the appropriate acid.

The following Examples illustrate the present invention but should not be construed as a limitation to the scope thereof.

15

#### Example 1

##### Preparation of 5-(4-chlorophenylthio)isocytosine

- Isocytosine (100g, 0.90 mole) and glacial acetic (1 L) were combined in a 2 L 3-neck round bottom flask equipped with an air stirrer, dropping funnel and thermometer. Neat bromine (154 g, 0.96 mole) was added portionwise over about 2.5 hours to the rapidly stirred suspension. After completion of the addition, the mixture was stirred overnight. The thick mass was vacuum filtered on an 18.5 cm Buchner funnel, washed with cold water (2 x 1L) to remove most of the bright yellow color, and resuspended in cold water with mechanical stirring. Concentrated ammonium hydroxide (about 75 mL) was added in portions until pH8 was sustained for at least 15 minutes. The mixture was filtered, the cake was washed with water and dried overnight in a vacuum oven at 120°C to give 5-bromoisocytosine as an off-white powder (78.6% yield).

4-Chlorobenzenethiol (18.8g, 0.13mole) was melted with a heat gun and

weighed directly into a 500 mL 3-neck round bottom flask maintained under an argon atmosphere. The flask was then equipped with a magnetic stirrer and a reflux condenser vented to a scrubbing tower containing household bleach. Dimethylformamide (170 mL), 5-bromoisocytosine (19.0g, 5 0.10mole), and potassium carbonate (18g, 0.13mole) were added and the reaction mixture was placed in an oil bath preheated to approximately 110°C. The turbid brown solution was stirred for 4 hours at 104-114°C, cooled slightly and then poured onto ice (900 g) and water with stirring. The mixture was acidified with 6M HCl (25 mL) to pH 6, and the white solid 10 was collected by vacuum filtration and washed with water. The damp cake was slurried with a mixture of diethyl ether (900 mL) and methanol (60 mL) for one hour. The solid was collected by filtration, washed with ether, and air dried to give 5-(4-chlorophenylthio)isocytosine as a white solid, mp 301-303°C, 21.6g (yield 85.0%).

15

#### Example 2

Preparation of 2-amino-5-(4-chlorophenylthio)-4-(trans-4-hydroxycyclohexylamino)pyrimidine

20 N,N-diisopropylformamide (31.0 g, 0.24 mole) and methylene chloride (550 mL) were combined in a 2 L 3-neck round bottom flask equipped with an air stirrer, dropping funnel, and reflux condenser. The apparatus was flushed with argon, and oxalyl chloride (33.4 g, 0.26 mole) was placed in the dropping funnel. The oxalyl chloride was added portionwise over 25 approximately 1.5 hours to the rapidly stirred solution. Stirring was continued for about 15 minutes after completion of the addition and then 5-(4-chlorophenylthio)isocytosine (21.6g, 0.085 mole) was added through a powder funnel. The mixture was brought to reflux and held for 1.5 - 2 hours until all solids dissolved. The mixture was cooled slightly, and excess 30 Vilsmeier reagent was destroyed by the slow, portionwise addition of saturated aqueous NaHCO<sub>3</sub> solution (500 mL) to pH 7. The aqueous phase was largely removed by aspiration into a 2 L vacuum flask, and the

organic extract was washed with water (3 x 500 mL) and brine (1 x 500 mL). The remaining organic extract was poured into a 1 L separatory funnel for the final phase split; it was then dried ( $\text{Na}_2\text{SO}_4$ ) and filtered through a silica gel bed (33 g, 2x 30 cm). The yellow filtrate was collected, and the bed was washed with additional  $\text{CH}_2\text{Cl}_2$  until the washings were nearly colorless. The combined filtrates were stripped in vacuo to an amber oil, and hexanes (300 mL) were added to the warm oil with rapid magnetic stirring. Crystallization of the product began quickly. The mixture was allowed to cool with stirring, chilled in ice/water, and the solid was collected by filtration, washed with hexanes and air dried to give 5-[(4-chlorophenyl)thio]-2-(diisopropylaminomethyleneamino)-4-chloropyrimidine as a white powder, mp 110-111°C, yield 25.3 g (77.7%).

5-[(4-chlorophenyl)thio]-2-(diisopropylaminomethyleneamino)-4-chloropyrimidine (9.7g, 0.025 mole) and trans-4-aminocyclohexanol hydrochloride (15.16g, 0.100 mole) were combined in absolute ethanol (97 mL), and triethylamine (0.2 mole, 28 mL) was added. The mixture was then refluxed for 3 - 5 days. The mixture was cooled to approximately room temperature and concentrated HCl (10 mL) was added. The mixture was then heated at reflux for 1 - 1.5 hours, cooled and stripped in vacuo. The solid residue was slurried in water (100 mL), and the solid was collected by filtration, washed with water (1 x 100 mL) and air-dried to give 2-amino-5-(4-chlorophenylthio)-4-(trans-4-hydroxycyclohexylamino)pyrimidine as a white solid, mp 196-197°C, yield 8.16 g (93.0%).

### Example 3

Preparation of 2-amino-5-(4-chlorophenylthio)-4-(2-hydroxyethylamino)pyrimidine

To 26 ml of a solution of 5-[(4-chlorophenyl)thio]-2-

(diisopropylaminomethyleneamino)-4-chloropyrimidine (5g, 0.130 mole) in dry ethanol was added ethanolamine (5g, 82 mmoles). The mixture was refluxed for 11 hrs. After cooling, 10 ml of concentrated hydrochloric acid was added, and this mixture was refluxed for 50 minutes and then spin  
5 evaporated at 60° C in vacuo. The resulting syrup was suspended in 400 ml of water and stirred with 100 ml of dichloromethane. Phases were separated and the aqueous phase was stirred again with 100 ml of dichloromethane. The pH was adjusted to 7 with 3N NaOH. A large precipitate formed in the organic phase. The aqueous phase was removed  
10 and the solids in the organic phase were collected by filtration and washed with dichloromethane. The crude product (1.35g) was suspended in 80 ml of ethanol, then heated to boiling, and filtered while hot. As the filtrate cooled, a cotton-like precipitate formed. The solids were collected by filtration, washed with ethanol, and dried in vacuo at 110° C for 15 hours.  
15 1.05g (42% yield) of a white solid was obtained. mp. 200° C.

#### Example 4

Preparation of 4-(4-acetylpiperazino)-2-amino-5-(4-chlorophenylthio)pyrimidine

20 To diisopropylformamide (14.1g, 109 mmoles) dissolved in 240 ml of dichloromethane was slowly added oxalyl chloride (14.1g, 111 mmoles) with stirring. Five minutes after the end of the addition, solid 5-(4-chlorophenylthio)isocytosine (10.1g, 40 mmoles) was added and washed in  
25 with 250 ml additional dichloromethane. The mixture was refluxed for 1 hour and 10 minutes. After cooling, it was poured into 450 ml of ice cold saturated NaHCO<sub>3</sub>. After separating the phases, this extraction was repeated on the organic layer. The organic layer was then washed with 500 ml of ice cold water and finally with 400 ml of brine. After drying over  
30 stirred Na<sub>2</sub>SO<sub>4</sub> for 4 hours, the suspension was filtered, and the filtrate was applied to a Silica Gel 60 (230-400 mesh, EM Science Co.) column (4 x 7 cm) and eluted with dichloromethane. The strongly uv absorbing

fractions were pooled and spin evaporated in vacuo at 45° C to give the intermediate chloropyrimidine as a syrup (24g). After dissolving in 100 ml of dry ethanol, the final volume was 124 ml.

- 5 To 26 ml of this solution was added 1-acetylpiperazine (4.65g, 36 mmoles). The mixture was refluxed for 11 hrs. After cooling, 10 ml of concentrated hydrochloric acid was added, and this mixture was refluxed for 45 minutes. Upon cooling a precipitate had formed which was removed by filtration. The filtrate was then spin evaporated at 60° C in vacuo. The  
10 resulting syrup was suspended in 400 ml of water and stirred with 100 ml of dichloromethane. Phases were separated and the aqueous phase was stirred again with 100 ml of dichloromethane. The pH was adjusted to 7 with 3N NaOH. The organic phase was washed twice with 450 ml of water then with 200 ml of brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration, the dried  
15 organic phase was applied to a Silica Gel (230-400 mesh) column (4 x 6 cm). The product was eluted with ethyl acetate and spin evaporated at 60° C in vacuo. The resulting material was redissolved in 5 ml of hot ethyl acetate. Upon the addition of hexanes, a solid formed. The solvents were removed by decanting and the solids were suspended in 40 ml of diethyl  
20 ether and boiled with stirring. The solids were collected by filtration, washed with hexanes, and dried in vacuo at 105° C. 300 mg (10% yield) of white powder was obtained. mp 140-141 ° C.

#### Example 5

- 25 Preparation of 2-amino-5-(4-chlorophenylthio)-4-(4-hydroxyanilino)pyrimidine hydrochloride

- Nitrogen was bubbled through a solution of 9g (23.5 mmol) 5-(4-chlorophenylthio)-2- (diisopropylaminomethyleneamino)-4-chloropyrimidine  
30 (see Example 2) in 200 mL of methanol for 10 minutes. Then 2.66 g of 4-aminophenol (24.4 mmol) was added and nitrogen bubbled through the

suspension for 5 minutes. The mixture was then tightly sealed and stirred until all in solution. After 2 days at 24°C, 50 ml of concentrated hydrochloric acid was added and the mixture refluxed for 100 minutes. After spin evaporation at 60°C, the solid was crystallized from hot ethanol and dried in vacuo at 105°C. 7.22 g (81%) of product as a pale yellow powder was obtained, mp 273-275°C.

#### Example 6

Preparation of 4-(4-acetoxyanilino)-2-amino-5-(4-chlorophenylthio)pyrimidine

1.25 g (3.28 mmole) of 2-amino-5-(4-chlorophenylthio)-4-(4-hydroxyanilino)pyrimidine hydrochloride (see Example 5) and 0.03g of 4-dimethylaminopyridine were dissolved in 3.9 g of dry N,N-dimethylformamide. 0.47 g acetic anhydride were added, and the container was sealed. After 2 days at 24°C, 100 mL of CH<sub>2</sub>Cl<sub>2</sub> were added to the reaction mixture and stirred with 150 mL of cold saturated aqueous NaHCO<sub>3</sub>. The organic layer was washed twice with 250 mL of water, then with 200 mL brine and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtering off the salt, the filtrate was applied to a Silica Gel 60 column (2.5 x 6.5 cm) which had been preequilibrated with hexanes. Eluates were 50 mL hexanes, a mixture of 150 mL hexanes and 150 mL CH<sub>2</sub>Cl<sub>2</sub>, and 500 mL CH<sub>2</sub>Cl<sub>2</sub>. Fractions with product, which was pure by TLC (EtOAc; Rf 0.6), were pooled and spin evaporated to a waxy solid. This solid was removed from the flash with the aid of hot hexanes, collected by filtration, and washed with hexanes. After drying in vacuo at 100°C for 16 hours, 0.19 g (15% yield) of a white powder was obtained, mp 178-180°C.

The following compounds were prepared by methods similar to those of the above indicated Examples:

	<u>Chemical Name</u>	<u>MP° C</u>
	2-amino-5-(4-chlorophenylthio)-4-(2-methoxyethylamino)pyrimidine	109
5	2-amino-5-(4-chlorophenylthio)-4-(2,3-dihydroxypropylamino) pyrimidine	158-159
	2-amino-5-(4-chlorophenylthio)-4-(1-hydroxymethyl-ethylamino) pyrimidine	200-201
	2-amino-5-(4-chlorophenylthio)-4-(1-dimethyl-2-hydroxyethylamino) pyrimidine	142-143
10	4-(4-Acetylhomopiperazino)-2-amino-5-(4-chlorophenylthio)pyrimidine	105-106
	2-Amino-5-(4-chlorophenylthio)-4-[2-hydroxy-1-(R)-ethyl]-ethylamino pyrimidine	119-121
	2-Amino-5-(4-chlorophenylthio)-4-[[2-(morpholino)ethylamino] pyrimidine	110-111
15	2-Amino-5-(4-chlorophenylthio)-4-(1-morpholinoamino) pyrimidine	160-162
	2-Amino-5-(4-chlorophenylthio)-4-(4-hydroxyphenethylamino) pyrimidine	177-182
20	trans-2-[N-(2-Amino-5-(4-chlorophenylthio))pyrimidin-4-yl]- aminomethylcyclohexanol	140-142
	4-[N-(2-Amino-5-(4-chlorophenylthio))pyrimidin-4-yl]-aminomethyl-N- acetylpiperidine	173-175
	1--[N-(2-Amino-5-(4-chlorophenylthio))pyrimidin-4-yl]- aminomethylcyclohexanol	226-227
25	4-(4-trans-Acetoxycyclohexylamino)-2-amino-5-(4-chlorophenylthio) pyrimidine	200-201
	2-Amino-5-(4-chlorophenylthio)-4-(4-trans-isobutyloxy- cyclohexylamino)pyrimidine	123-124
	2-Amino-5-(4-chlorophenylthio)-4-(4-trans-trimethylacetoxo- cyclohexylamino)pyrimidine	170-171
30	2-Amino-5-(4-chlorophenylthio)-4-(4-trans-propionyloxy- cyclohexylamino)pyrimidine	150-152
	2-Amino-5-(4-chlorophenylthio)-4-(4-trans-benzoyloxyoxy- cyclohexylamino)pyrimidine	159-169

35

	2-Amino-5-(4-chlorophenylthio)-4-(4-trans-(4-chlorobenzoyloxy)-cyclohexylamino)-pyrimidine	155-156
	2-Amino-5-(4-chlorophenylthio)-4-(4-trans-L-valyloxycyclohexylamino)pyrimidine	foam
5	4-(4-Acetoxyphenylamino)-2-amino-5-(4-chlorophenylthio)pyrimidine	178-180
	2-Amino-4-phenylamino-5-(4-chlorophenylthio)pyrimidine	169-170
	2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-hydroxyphenylthio)pyrimidine	below 100
	2-Amino-4-(acetamidophenylamino)-5-(4-chlorophenylthio)pyrimidine	217-218
10	2-[N-{2-Amino-5-(4-chlorophenylthio)}pyrimidin-4-yl]-amino-1,3-propanediol	200-201
	2-Amino-5-(4-chlorophenylthio)-4-(4-hydroxy-3-nitro-anilino)pyrimidine	235

The following Examples illustrate representative pharmaceutical compositions wherein the "Active Ingredient" may be any compound of Formula I or a pharmaceutically acceptable salt thereof.

#### Example A - Tablet Composition

	<u>mg/tablet</u>
20 (a) Active Ingredient	250
(b) Lactose B.P.	210
(c) Povidone B.P.	15
(d) Sodium Starch Glycollate	20
(e) Magnesium Stearate	5

25

The composition is prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

#### 30 Example B - Capsule Composition

A capsule composition is prepared by admixing the ingredients and filling into a two-part hard gelatin capsule.

	<u>mg/capsule</u>
(a) Active Ingredient	250
(b) Lactose B.P.	143
(c) Sodium Starch Glycollate	25
5 (d) Magnesium Stearate	2

#### Example C - Injectable Composition

(a) Active Ingredient	0.200 g
(b) Hydrochloric Acid Solution 0.1 M or	
10 Sodium Hydroxide Solution 0.1M to pH	4.0 to 7.0
(c) Sterile Water q.s. to	10 ml

The active ingredient is dissolved in most of the water (35° - 40° C) and the pH is adjusted to between 4.0 and 7.0. The batch is then made up to  
 15 volume with sterile water and filtered through a sterile micropore filter into a sterile amber glass vial (type 1) and sealed with sterile closures and overseals.

The compounds of the invention were assayed for neurotrophic activity as  
 20 follows:

#### A. Screen for NGF-like Activity:

Cultured PC12 cells (rat adrenal pheochromocytoma from ATCC) have  
 25 receptors for NGF. Responses include promotion of neurite outgrowth and elevation of choline acetyltransferase(ChAT) (L.A. Greene and A.S. Tischler, Cell Neurobiol., 3, 373 (1982)).

The following assay is modified from that described in HL White and PW  
 30 Scates, Neurochem. Res., 16, 63 (1991). PC12 cells were cultured at 37° C in RPMI supplemented with HEPES buffer, pH7.5 (to 10 mM), fetal bovine serum, horse serum, glutamine, penicillin, streptomycin and non-

essential amino acids. Cultures were split 1:3 every 3 to 4 days.

Exponentially dividing cells were plated into fresh medium on collagen-coated 12-well plastic dishes ( $10^5$  cells/well).

After allowing one day for cell attachment, the medium was replaced with  
5 low serum medium, with or without test compounds with each condition in triplicate. The medium may contain up to 0.2 % ethanol, which was used as a solvent for most compounds tested. Cells were examined for morphological changes using an Olympus IMT-2 inverted research microscope. After 3 days incubation with test compounds, medium was  
10 removed and replaced with 0.2 ml of lysis and ChAT assay mixture. The plates were incubated at  $37^{\circ}$  C for 2 hours and then placed into a freezer at  $-20^{\circ}$  C.

Compounds are judged NGF-like in this primary screen if they (1) increase  
15 the activity of ChAT, (2) enhance NGF-stimulated neurite outgrowth or (3) potentiate or appear additive with the action of NGF itself.

#### B. Choline Acetyltransferase (ChAT) Assays:

20 The assay mixture contained 100 mM phosphate, pH7.4, 0.1% NP-40, 150 mM NaCl, 1.5 mM choline, 10 mM EDTA, 0.1 mM eserine, 0.1 mM acetyl-coenzyme A and about 0.5 uCi (40-70 Ci/mol) [ $^{14}$ C]acetyl-coenzyme A in each ml of mixture. Thawed and lysed cell reaction mixtures were diluted to 1 ml with water and transferred to 7 ml scintillation vials containing 5 ml  
25 of extraction/scintillation fluid solution (50 mg triphenyl borate, 50 mg PPO, 20 mg POPOP per 100 ml of 20% acetonitrile/80% toluene) and vortexed for 10 seconds. After all diluted well contents were transferred and mixed, all the vials were vortexed again for 30 seconds, rotated for about 2 hours, and then  
30 vortexed once more. The vials were centrifuged at 3000 rpm ( $r_{\text{max}}=16$  cm) for 15 minutes and then counted in a Beckman LS6500 scintillation counter. Background counts from reaction mixtures with extracts from

nonstimulated cells (no NGF and no test compound) were subtracted from reaction product counts before comparisons of ChAT activities were made.

C. In Vitro Activity Data


5

The following data were obtained for representative compounds of the invention which (1) increased the activity of choline acetyltransferase (ChAT), (2) enhanced NGF-stimulated neurite outgrowth and/or (3) potentiated or appeared additive with the action of NGF itself. The concentration at which the test compound doubled the ChAT activity over the activity with NGF alone (no test compound) was recorded as the EC<sub>2x</sub> value:

	<u>Compound of</u>	<u>EC<sub>2x</sub> (uM)</u>
15	Example 2	0.04
	Example 3	0.35
	Example 4	0.2
	Example 5	0.07
	Example 6	0.1

## CLAIMS

1. A compound of the formula



wherein

R<sub>1</sub> is NHR<sub>4</sub>, wherein R<sub>4</sub> is C6-10 aryl, C2-10alkyl, (C1-6alkyl)<sub>j</sub>(C3-9cycloalkyl)(CH<sub>2</sub>)<sub>q</sub> or (C1-6alkyl)<sub>j</sub>(C6-10aryl)(CH<sub>2</sub>)<sub>q</sub>, wherein j is 0-2 and q is 0-6, or (C1-6alkyl)<sub>j</sub>(C4-9heterocycloalkyl)(CH<sub>2</sub>)<sub>q</sub> wherein j is 0-2, q is 0-6 and the heterocyclic ring contains one or more heteroatoms which may be the same or different and are O, S, N or NR' (wherein R' is hydrogen, C1-6 alkyl, hydroxyC2-6 alkyl, mercaptoC2-6alkyl, C1-6alkyloxyC2-6alkyl, C1-6alkylthioC2-6alkyl, C6-10arylcarbonyl, C1-7alkylcarbonyl, C1-7alkylsulfonyl or C6-10arylsulfonyl);

or

R<sub>1</sub> is piperazino or homopiperazino wherein the 4-N is substituted with a carbonylR<sub>5</sub> or sulfonylR<sub>5</sub>, wherein R<sub>5</sub> is

H (excluding sulfonyl),  
 C1-10alkyl,  
 C3-10alkenyl,  
 C3-10alkynyl,  
 C1-6alkyloxy,  
 C1-6alkyloxyC1-6alkyl,  
 C1-6alkylthioC1-6alkyl,  
 C1-6alkylamino,

C6-10aryl(CH<sub>2</sub>)<sub>q</sub> wherein q is 0-6,  
C6-10aryloxy(CH<sub>2</sub>)<sub>q</sub> wherein q is 0-6,  
C6-10arylamino(CH<sub>2</sub>)<sub>q</sub> wherein q is 0-6,  
(C1-6alkyl)<sub>j</sub>(C3-9cycloalkyl)(CH<sub>2</sub>)<sub>q</sub> wherein j is 0-2 and q is 0-6,  
5 or (C1-6alkyl)<sub>j</sub>(C4-9heterocycloalkyl)(CH<sub>2</sub>)<sub>q</sub> wherein j is 0-2, q  
is 0-6 and the heterocyclic ring contains one or more  
heteroatoms which may be the same or different and are O, S,  
N or NR', wherein R' is hydrogen, C1-6alkyl, hydroxyC2-6alkyl,  
mercaptoC2-6alkyl, C1-6alkyloxyC2-6alkyl, C1-6alkylthioC2-  
10 6alkyl, C6-10arylcarbonyl, C1-7alkylcarbonyl, C1-7alkylsulfonyl  
or C6-10arylsulfonyl,

and wherein C atoms of R<sub>4</sub> and R<sub>5</sub> may optionally be substituted with one  
or more substituents selected from the group consisting of

hydroxyl,  
15 halogen,  
thiol,  
oxo,  
thioxo,  
carboxy,  
20 carboxamide,  
C1-7alkyl carbonyl,  
C1-7alkyl thiocarbonyl,  
C1-8alkyloxy,  
C1-8alkylthio,  
25 C1-8alkylsulfinyl,  
C1-8alkylsulfonyl,  
C1-5alkyloxyC1-5alkyl,  
C1-5alkylthioC1-5alkyl,  
C1-5alkylsulfinylC1-5alkyl, and  
30 C1-5alkylsulfonylC1-5alkyl;

R<sub>2</sub> is H or NH<sub>2</sub>;

R<sub>3</sub> is H;

X is a C6-10 aryl ring optionally substituted with one or more substituents

5 selected from the group consisting of

halogen,  
hydroxyl,  
C1-6alkyl,  
hydroxyC1-6alkyl,  
10 oxoC2-7alkyl,  
C2-7alkenyl,  
C2-7alkynyl,  
C1-6alkoxy,  
CF<sub>3</sub>,  
15 CF<sub>3</sub>C1-6alkyl,  
OCF<sub>3</sub>, and  
CF<sub>3</sub>C1-6alkoxy;

or pharmaceutically acceptable esters, amides, esters, amides, salts or  
20 solvates thereof.

2. A compound of Claim 1 wherein X is substituted phenyl, and  
pharmaceutically acceptable esters, amides, salts or solvates thereof.

25 3. A compound of Claim 1 wherein R<sub>1</sub> is C1-10alkylcarbonylpiperizino,  
hydroxyC3-9cycloalkylamino, or hydroxyC6-10arylamino and X is  
substituted phenyl, and pharmaceutically acceptable esters, amides, salts  
or solvates thereof.

30 4. A compound of Claim 1 wherein R<sub>1</sub> is 4-acetylpiperazino, 4-  
oxocyclohexylamino, trans-4-hydroxycyclohexylamino, 4-hydroxyanilino, or  
4-(2-hydroxyethylamino); X is phenyl optionally substituted with 4-chloro,

2,4 dichloro, 4- bromo, 2-fluoro-4-chloro, 2-chloro-4-fluoro, 2-methyl-4-chloro, 4-methyl, or 4-ethyl; and R<sub>2</sub> is NH<sub>2</sub>; and pharmaceutically acceptable esters, amides, salts or solvates thereof.

- 5 5. A compound selected from the group consisting of:  
4-acetylpiperazino-2-amino-5-(4-chlorophenylthio)pyrimidine  
4-acetylpiperazino-2-amino-5-(2,4-dichlorophenylthio)pyrimidine  
4-acetylpiperazino-2-amino-5-(4-bromophenylthio)pyrimidine  
4-acetylpiperazino-2-amino-5-(2-fluoro-4-chlorophenylthio)pyrimidine  
10 4-acetylpiperazino-2-amino-5-(2-chloro-4-fluorophenylthio)pyrimidine  
4-acetylpiperazino-2-amino-5-(2-methyl-4-chlorophenylthio)pyrimidine  
4-acetylpiperazino-2-amino-5-(4-methylphenylthio)pyrimidine  
4-acetylpiperazino-2-amino-5-(4-ethylphenylthio)pyrimidine  
2-amino-4-oxocyclohexylamino-5-(4-chlorophenylthio)pyrimidine  
15 2-amino-4-oxocyclohexylamino-5-(2,4-dichlorophenylthio)pyrimidine  
2-amino-4-oxocyclohexylamino-5-(4-bromophenylthio)pyrimidine  
2-amino-4-oxocyclohexylamino-5-(2-fluoro-4-chlorophenylthio)pyrimidine  
2-amino-4-oxocyclohexylamino-5-(2-chloro-4-fluorophenylthio)pyrimidine  
2-amino-4-oxocyclohexylamino-5-(2-methyl-4-chlorophenylthio)pyrimidine  
20 2-amino-4-oxocyclohexylamino-5-(4-methylphenylthio)pyrimidine  
2-amino-4-oxocyclohexylamino-5-(4-ethylphenylthio)pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(4-chlorophenylthio)pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(2,4-dichlorophenylthio)pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(4-bromophenylthio)pyrimidine  
25 2-amino-4- hydroxycyclohexylamino-5-(2-fluoro-4-chlorophenylthio)  
pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(2-chloro-4-fluorophenylthio)  
pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(2-methyl-4-chlorophenylthio)  
30 pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(4-methylphenylthio)pyrimidine  
2-amino-4- hydroxycyclohexylamino-5-(4-ethylphenylthio)pyrimidine

- 2-amino-4- hydroxyanilino-5-(4-chlorophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(2,4-dichlorophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(4-bromophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(2-fluoro-4-chlorophenylthio)pyrimidine  
5 2-amino-4- hydroxyanilino-5-(2-chloro-4-fluorophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(2-methyl-4-chlorophenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(4-methylphenylthio)pyrimidine  
2-amino-4- hydroxyanilino-5-(4-ethylphenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-chlorophenylthio)pyrimidine  
10 2-amino-4-(2-hydroxyethylamino)-5-(2,4-dichlorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-bromophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(2-fluoro-4-chlorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(2-chloro-4-fluorophenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(2-methyl-4-chlorophenylthio)  
15 pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-methylphenylthio)pyrimidine  
2-amino-4-(2-hydroxyethylamino)-5-(4-ethylphenylthio)pyrimidine  
2-Amino-5-(2-chloro-4-ethylphenylthio)-4-(trans-4-hydroxycyclohexylamino)  
pyrimidine  
20 2-Amino-5-(2,6-dichlorophenylthio)-4-(trans-4-hydroxycyclohexylamino)  
pyrimidine  
2-Amino-5-(4-chloro-2-methylphenylthio)-4-(trans-4-  
hydroxycyclohexylamino)pyrimidine  
2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(4-  
25 trifluoromethylphenylthio)pyrimidine  
2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(4-methylphenylthio)  
pyrimidine  
2-Amino-5-(4-chloro-2-fluorophenylthio)-4-(trans-4-  
hydroxycyclohexylamino)pyrimidine  
30 2-Amino-5-(4-chloro-2-methylphenylthio)-4-(trans-4-  
hydroxycyclohexylamino)pyrimidine

- 2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(4-methylphenylthio)  
pyrimidine
- 2-Amino-4-(trans-4-hydroxycyclohexylamino)-5-(phenylthio)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-hydroxycyclohexylamino)  
5 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-2-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(cis-4-hydroxycyclohexylamino)  
pyrimidine
- 10 2-Amino-5-(4-chlorophenylthio)-4-(cis-3-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(cis-2-hydroxycyclohexylamino)  
pyrimidine
- 2-Amino-5-(2,4-dichlorophenylthio)-4-(4-oxocyclohexylamino)pyrimidine
- 15 2-Amino-5-(2,4,6-trichlorophenylthio)-4-(4-oxocyclohexylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-4-(hydroxymethyl)  
cyclohexylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-(hydroxymethyl)  
cyclohexylamino)pyrimidine
- 20 2-Amino-5-(4-chlorophenylthio)-4-(cis-4-(hydroxymethyl)cyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-4-hydroxycyclohexylmethylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-hydroxycyclopentylamino)  
25 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-2-hydroxycyclopentylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(cis-3-hydroxycyclopentylamino)  
pyrimidine
- 30 2-Amino-5-(4-chlorophenylthio)-4-(cis-2-hydroxycyclopentylamino)  
pyrimidine

- 2-Amino-5-(4-chlorophenylthio)-4-(trans-3-(hydroxymethyl)  
cyclopentylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(trans-2-(hydroxymethyl)  
cyclopropylmethylamino)pyrimidine
- 5 2-Amino-5-(4-chlorophenylthio)-4-(cis-2-(hydroxymethyl)  
cyclopropylmethylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(1-hydroxycyclopropylmethylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(1-hydroxycyclopentylmethylamino)  
10 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxy-1-methyl(ethylamino))  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(1-hydroxymethyl-ethylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(1,1-dimethyl-2-hydroxy(ethylamino))  
15 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(1-hydroxymethyl-2-hydroxy(ethylamino))  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxy-1-hydroxymethyl-1-methyl  
(ethylamino))pyrimidine
- 20 2-Amino-5-(4-chlorophenylthio)-4-(tris(hydroxymethyl)methylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(2,3-dihydroxypropylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(3,4-dihydroxybutylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(2-methoxyethylamino)pyrimidine
- 25 2-Amino-5-(4-chlorophenylthio)-4-(2-(2-hydroxyethylamino)ethylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-((2-aminoethyl)(2-hydroxyethyl)amino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxyethylamino)pyrimidine
- 30 2-Amino-5-(4-chlorophenylthio)-4-(4-(2-hydroxyethyl)piperazinoamino)  
pyrimidine

- 2-Amino-5-(2,4-dichlorophenylthio)-4-(4-(2-hydroxyethyl)piperazinoamino)pyrimidine
- 2-Amino-5-(2-chloro-4-ethylphenylthio)-4-(4-acetylpiperazino)pyrimidine
- 2-Amino-5-(2,4-dichlorophenylthio)-4-(4-acetylpiperazino)pyrimidine
- 5 2-Amino-5-(2,6-dichlorophenylthio)-4-(4-acetylpiperazino)pyrimidine
- 2-Amino-5-(4-chloro-2-methylphenylthio)-4-(4-acetylpiperazino)pyrimidine
- 2-Amino-4-(4-acetylpiperazino)-5-(4-trifluoromethylphenylthio)pyrimidine
- 2-Amino-5-(2-chloro-4-fluorophenylthio)-4-(4-acetylpiperazino)pyrimidine
- 2-Amino-5-(4-chloro-2-methylphenylthio)-4-(4-acetylpiperazino)pyrimidine
- 10 2-Amino-4-(4-acetylpiperazino)-5-(4-methylphenylthio)pyrimidine
- 2-Amino-4-(4-acetylpiperazino)-5-(phenylthio)pyrimidine
- 5-(4-Chlorophenylthio)-4-(4-acetylpiperazino)pyrimidine
- 5-(2,4-Dichlorophenylthio)-4-(4-acetylpiperazino)pyrimidine
- 4-(4-Acetoxyanilino)-2-amino-5-(4-chlorophenylthio)pyrimidine
- 15 4-(4-Acetylhomopiperazino)-2-amino-5-(4-chlorophenylthio)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-[2-hydroxy-1-(R-ethyl)-ethylamino]pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-[[2-(morpholino)ethylamino]pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(1-morpholinoamino)pyrimidine
- 20 2-Amino-5-(4-chlorophenylthio)-4-(4-hydroxyphenethylamino)pyrimidine
- 2-Amino-4-(trans-2-hydroxycyclohexylaminomethyl)-5-(4-chlorophenylthio)pyrimidine
- 2-Amino-4-(4-aminomethyl-N-acetylpiperidiny)-5-(4-chlorophenylthio)pyrimidine
- 25 2-Amino-4-(1-hydroxy-1-aminomethylcyclohexyl)-5-(4-chlorophenylthio)pyrimidine
- 4-(4-trans-Acetoxy-cyclohexylamino)-2-amino-5-(4-chlorophenylthio)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-isobutryloxy-cyclohexylamino)
- 30 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-trimethylacetoxycyclohexylamino)pyrimidine

- 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-propionyloxy-cyclohexylamino)  
pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-benzoyloxy-cyclohexylamino)  
pyrimidine
- 5 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-(4-chlorobenzoyloxy)-  
cyclohexylamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(4-trans-L-valyloxycyclohexylamino)  
pyrimidine
- 4-(4-Acetoxyphenylamino)-2-amino-5-(4-chlorophenylthio)pyrimidine
- 10 2-Amino-4-phenylamino-5-(4-chlorophenylthio)pyrimidine
- 2-Amino-4-(4-trans-hydroxycyclohexylamino)-5-(4-hydroxyphenylthio)  
pyrimidine
- 2-Amino-4-(acetamidophenylamino)-5-(4-chlorophenylthio)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(bis-hydroxymethylmethylamino)  
15 pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(4-hydroxy-3-nitro-anilino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(hydroxyamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(methoxyamino)pyrimidine
- 2-Amino-5-(4-chlorophenylthio)-4-(2-hydroxyethoxyamino)pyrimidine
- 20 and pharmaceutically acceptable esters, amides, salts or solvates thereof.

6. A pharmaceutical composition comprising a compound according to  
claim 1 and a pharmaceutically acceptable carrier therefor.
- 25 7. A pharmaceutical composition comprising a compound according to  
claim 5 and a pharmaceutically acceptable carrier therefor.
8. A method of treating a mammal having a neurodegenerative or  
neurological disorder of the central or peripheral nervous system with a  
30 therapeutically effective amount of a compound of claim 1.
9. A method of treating a mammal having a neurodegenerative or

neurological disorder of the central or peripheral nervous system with a therapeutically effective amount of a compound of claim 5.

10. A method according to claim 8 wherein the disorder is Alzheimer's  
5 disease.

11. A method according to claim 9 wherein the disorder is Alzheimer's disease.

10 12. A method according to claim 8 wherein the disorder is peripheral neuropathy.


13. A method according to claim 9 wherein the disorder is peripheral neuropathy

15

14. A method according to claim 8 wherein the disorder is senile dementia.

15. A method according to claim 9 wherein the disorder is senile dementia

16. A compound of the formula



5 wherein X is a C6-10 aryl ring optionally substituted with one or more substituents selected from the group consisting of

- halogen,
- C1-6alkyl,
- hydroxyC1-6alkyl,
- 10 oxoC2-7alkyl,
- C2-7alkenyl,
- C2-7alkynyl,
- C1-6alkoxy,
- CF<sub>3</sub>,
- 15 CF<sub>3</sub>C1-6alkyl,
- OCF<sub>3</sub>, and
- CF<sub>3</sub>C1-6alkoxy.

17. A compound selected from the group consisting of 5-(4-chlorophenylthio)-2-(diisopropylaminomethyleneamino)-4-chloropyrimidine  
 20 and 5-(2,4-dichlorophenylthio)-2-(diisopropylaminomethyleneamino)-4-chloropyrimidine.

18. 2-Amino-5-(4-chlorophenylthio)-4-(trans-4-hydroxycyclohexylamino)pyrimidine.

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 00/09004

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/48 C07D239/46 A61K31/506 A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 154 551 A (G.H. HITCHINGS) 27 October 1964 (1964-10-27) claims; examples 3,17,19; table I	1,2,6,7
A	EP 0 826 674 A (SUMITOMO) 4 March 1998 (1998-03-04) page 1 -page 11; tables	1,6-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

2 August 2000

Date of mailing of the international search report

17/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Francois, J

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter. Application No

PCT/US 00/09004

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3154551 A	27-10-1964	GB 951431 A GB 951432 A	
EP 826674 A	04-03-1998	CA 2217034 A WO 9631488 A JP 8333349 A	10-10-1996 10-10-1996 17-12-1996


# SYNTHESIS AND ANTIINFLAMMATORY PROPERTIES OF o-CARBOXYPHENYLAMINO PYRIMIDINES

V. K. Karn, I. S. Tat'yanchenko,  
V. A. Portnyagina, N. A. Mokhort,  
T. K. Ryabukha, and A. V. Vinnikova

UDC 616.281:547.853.3].012.1

Pyrimidine derivatives substituted with an o-carboxyphenylamino group at the 2, 4, or 5 position of the pyrimidine ring are physiologically active compounds [1-5].

The aim of the present work is to synthesize new o-carboxyphenylaminopyrimidines, with a phenylamino-, hydrazino-, or o-carboxyphenylamino group in the 2 position (Ia-f) and to study their antiinflammatory activity.



Ia: R = C<sub>6</sub>H<sub>5</sub>, R<sup>1</sup> = R<sup>2</sup> = H; Ib: R = NH<sub>2</sub>, R<sup>1</sup> = R<sup>2</sup> = H;  
Ic: R<sup>1</sup> = Br, R<sup>2</sup> = CH<sub>3</sub>; Id: R<sup>1</sup> = H, R<sup>2</sup> = COOH;  
Ie: R<sup>1</sup> = H, R<sup>2</sup> = Cl; If: R<sup>1</sup> = H, R<sup>2</sup> = CH<sub>3</sub>;  
Ic-f: R = C<sub>6</sub>H<sub>4</sub>COOH-o

Compounds Ia-f were obtained by the reaction of 2-chloro-4-(o-carboxyphenylamino)pyrimidines [6] with aniline, hydrazine, or anthranilic acid. The pyrimidines Ic-f were isolated as the hydrochlorides.

The 4-(o-carboxyphenylamino)pyrimidines Ia-f are yellow, crystalline substances, soluble in DMFA, DMSO, dilute acids, and bases; their properties are given in Table 1. The purity of compounds Ia-f were checked by TLC on UV 254 Silufol plates (ChSSR). Two solvent systems were used as eluents: 1) n-butanol-acetic acid-water (4:1:5); 2) alcohol-25% aqueous ammonia (10:1).

The IR spectra of compounds Ia-f (KBr pellets) showed absorptions due to stretching vibrations at 3400 cm<sup>-1</sup> (OH and NH), 1600-1620 cm<sup>-1</sup> (C=O), and 1580 cm<sup>-1</sup> (C=C and C=N of the pyrimidine ring), and absorptions due to deformation vibrations at 1450 cm<sup>-1</sup> (NH and OH of the pyrimidine ring), 1220-1240 cm<sup>-1</sup> (C=C), and 750 cm<sup>-1</sup> (pyrimidine ring CH).

## EXPERIMENTAL CHEMISTRY

Infrared spectra were taken on a Perkin-Elmer instrument (Sweden), UV spectra of ethanol solutions on an MPS-5000 spectrophotometer (Japan), c = 1·10<sup>-3</sup> moles/liter.

**2-Phenylamino-4-(o-carboxyphenylamino)pyrimidine (Ia).** To 4.6 g (0.2 moles) of metallic sodium dissolved in 50 ml of absolute methanol was added 18.6 g (0.2 moles) of aniline and 24.9 g (0.1 moles) of 2-chloro-4-(o-carboxyphenylamino)pyrimidine. The reaction mixture was heated in a sealed tube at 110°C for 6 h, cooled, the precipitated sodium chloride filtered off, the filtrate diluted with water and neutralized with 50% acetic acid to pH 6.0. The precipitate was filtered off, washed with water and ethyl alcohol, and recrystallized from ethanol.

**2-Hydrazino-4-(o-carboxyphenylamino)pyrimidine (Ib).** A stirred mixture of 24.9 g (0.1 moles) of 2-chloro-4-(o-carboxyphenylamino)pyrimidine and 10 g (0.2 moles) of hydrazine hydrate in 30 ml of methanol was heated under reflux on a water bath for 3 h. The precipitated material was filtered off and recrystallized from 50% aqueous ethanol.

**Hydrochloride of 2,4-Bi-(o-carboxyphenylamino)-5-bromo-6-methylpyrimidine (Ic).** A mixture of 34.2 g (0.1 moles) of 2-chloro-4-(o-carboxyphenylamino)-5-bromo-6-methylpyrimidine

Kiev Scientific-Research Institute of Pharmacology and Toxicology. Translated from *Khimiko-farmatsevticheskii Zhurnal*, Vol. 17, No. 11, pp. 1304-1307, November, 1983. Original article submitted January 12, 1983.

TABLE 1. o-Carboxyphenylaminopyrimidines Ia-f

Compound	Yield, %	Melting point, °C	Found, %		Empirical formula	Calculated, %		R <sub>f</sub> · 100 in system		UV spectra. λ <sub>max</sub> in ethanol, nm
			N	Cl		N	Cl	1	2	
Ia	81	279-80	18.30	—	C <sub>11</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub>	18.28	—	41	74	214, 274, 328
Ib	80	229-31	18.88	—	C <sub>11</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub>	18.56	—	33	52	216, 242, 319
Ic	84	298-9	11.79	7.55	C <sub>11</sub> H <sub>8</sub> BrN <sub>2</sub> O <sub>2</sub> ·HCl	11.08	7.39	62	48	229, 283, 336
Id	84	200	12.83	8.21	C <sub>11</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub> ·HCl	13.01	8.23	14	20	284, 348
Ie	80	210	14.30	8.86	C <sub>11</sub> H <sub>8</sub> ClN <sub>2</sub> O <sub>2</sub> ·HCl	14.55	9.22	64	52	234, 279, 336
If	80	285	14.18	8.58	C <sub>11</sub> H <sub>8</sub> N <sub>2</sub> O <sub>2</sub> ·HCl	13.87	8.64	64	45	232, 280, 328

TABLE 2. Antiinflammatory Properties of the o-Carboxyphenylaminopyrimidines Ia-f

Compound	LD <sub>50</sub> , mg/kg (intraperitoneally)	% decrease of formalin edema of the paw	Increase in threshold of pain sensitivity in mice, %	Antipyretic action in rats (Δt°)
Ia	1130	28.5±4.4	127.3±17.6	1.5±0.18
Ib	640	13.4±6.0	—	—
Ic	330	9±3.2	53±7.4	1.9±0.26
Id	460	48±6.0	62±4.6	2.0±0.13
Ie	550	34±4.9	54±7.7	2.3±0.9
If	400	45±3.2	74±6.0	1.3±0.22
Sodium mefenamate	150	30.6±7.8	55.1±5.0	1.5±0.22

and 13.85 g (0.11 moles) of anthranilic acid was heated on an oil bath at 100°C for 2 h. The precipitate formed was filtered off, washed with alcohol, and recrystallized from 50% acetic acid. Compounds Id-f were obtained in the same way from substituted 2-chloro-4-(o-carboxyphenylamino)pyrimidine and anthranilic acid.

#### EXPERIMENTAL BIOLOGY

A study was made of the acute toxicity, antiinflammatory, analgesic, and antipyretic activity of the 4-(o-carboxyphenylamino)pyrimidines Ia-f. The data obtained are given in Table 2.

Acute toxicity was determined by intraperitoneal injection into white mice of both sexes weighing 20-25 g; antiinflammatory and antipyretic action on rats of both sexes weighing 150-200 g.

Antiinflammatory action of the substances was determined from observations of edema of the rear paw of the rat, induced by the supplantar injection of 2% formalin. The test compounds were injected intraperitoneally as suspensions in starch at a dosage of 1/10 of the LD<sub>50</sub> 30 min before the injection of formalin. The volume of the paw was measured plethymographically 4 h after the injection of the inflammatory agent.

The antipyretic activity of the compounds was studied in tests on rats with milk fever caused by the injection of boiled skimmed cow's milk heated to 37-40°C (intramuscularly; 1 ml per 100 g of body weight). Compounds Ia-f were injected at the peak of the fever and the antipyretic action monitored over a period of 3 h.

The analgesic activity was studied on white mice weighing 20-25 g by the method described in [7, 8] by determining the threshold of sensitivity of heat. Pyrimidines Ia-f have low toxicity with LD<sub>50</sub> of 330-1130 mg/kg. The toxicity depends somewhat on chemical structure. The 2-(o-carboxyphenylamino)pyrimidines are more toxic than their analogs with an unsubstituted phenylamino or hydrazino group in the 2 position of the pyrimidine ring. The most toxic compound was Ic — 2,4-di(o-carboxyphenylamino)-5-bromo-6-methylpyrimidine.

Compounds Ia-f possess antiinflammatory properties and suppressed the development of formalin edema of the paw. The most active compounds were the 2,4-di(o-carboxyphenylamino)-pyrimidines Ic-f.

All the compounds also exhibited analgesic properties: The most active was 2-phenylamino-4-(o-carboxyphenylamino)pyrimidine Ia.

These compounds exhibited antipyretic action lowering the body temperature of a rat with milk fever. Most active were the 2,4-di(o-carboxyphenylamino)pyrimidines. In this group of compounds, preparation Ia - 2,4-di(o-carboxyphenylamino)-6-chloropyrimidine had the greatest antipyretic effect.

Thus, compounds Ia-f are less toxic than sodium mefenamate or brufen, and exhibit anti-inflammatory, analgesic, and antipyretic action.

#### LITERATURE CITED

1. T. Ueda and J. Fox, *J. Med. Chem.*, **6**, 697-701 (1963).
2. E. Falch, J. Wels, and J. Natvig, *J. Med. Chem.*, **11**, 608-611 (1968).
3. C. Völcker, M. Schönfeld, and H. Beyer, *Z. Chem.*, **8**, 103-104 (1968).
4. M. Yanai and T. Kuraishi, *Kagaku Zasshi*, **80**, 1181-1183 (1959).
5. FRG Patent No. 2735919 (1977).
6. V. K. Karp, V. A. Portnyagina, and I. S. Barkova, *Khim. Geterotsikl. Soedin.*, No. 9, 1252-1254 (1977).
7. E. Komlos and M. Porzasz, *Acta Physiol. Acad. Sci. Hung.*, **1**, 77-83 (1950).
8. F. P. Trinus, N. A. Mokhort, and B. M. Klebanov, *Nonsteroid Antiinflammatory Agents* [in Russian], Kiev (1975).


#### BROMINE ANALOGS OF QUINOXIDINE, DIOXIDINE, AND AMIDES OF DI-N-OXIDES OF 3-HYDROXYMETHYLQUINOXALINE-2-CARBOXYLIC ACID

I. S. Musatova, A. S. Elina,  
N. P. Solov'eva, L. M. Polukhina,  
N. Yu. Moskalenko, and G. N. Pershin

UDC 615.281:547.863.11].021.1

We investigated the synthesis of bromine analogs of the biologically-active quinoxaline derivatives quinoxidine, dioxidine, and amides of di-N-oxides of 3-hydroxymethylquinoxaline-2-carboxylic acid [1-3] in order to study their biological activity.

The bromine analogs of quinoxidine [2,3-bis(acetoxymethyl)-7-bromoquinoxaline-di-N-oxide (I)] and dioxidine [2,3-bis(hydroxymethyl)-7-bromoquinoxaline-di-N-oxide (II)] were synthesized as indicated in the scheme below from 2,3-dimethyl-7(6)-bromoquinoxaline-di-N-oxide (III) by means of the intermediate 2,3-bis(bromomethyl)-7(6)-bromoquinoxaline-di-N-oxide (IV).



Amides of 3-hydroxymethyl-7-bromoquinoxaline-2-carboxylic acid di-N-oxide (XXIIIa-i) were synthesized from 2-carbathoxy-3-methyl-7-bromoquinoxaline-di-N-oxide (V), which was in turn prepared by a known method: the reaction of 5(6)-bromobenzofuroxane (VI) with esters of acetoacetic acid in the presence of various basic reagents [4, 5]. These authors recommended the use of the 7- and 6-bromo isomers of 2-carbalkoxy-3-methylquinoxaline-di-N-oxide

S. Ordzhonikidze All-Union Scientific-Research Institute of Pharmaceutical Chemistry, Moscow. Translated from *Khimiko-farmatsevticheskii Zhurnal*, Vol. 17, No. 11, pp. 1307-1312, November, 1983. Original article submitted February 28, 1983.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**